...
机译:
Wake Forest Univ;
机译:Recurrence rates in patients with HER2+breast cancer who achieved a pathological complete response after neoadjuvant pertuzumab plus trastuzumab followed by adjuvant trastuzumab: a real-world evidence study
机译:A randomized, 3-arm, neoadjuvant, phase 2 study comparing docetaxel plus carboplatin plus trastuzumab plus pertuzumab (TCbHP), TCbHP followed by trastuzumab emtansine and pertuzumab (T-DM1+P), and T-DM1+P in HER2-positive primary breast cancer
机译:Neoadjuvant Trastuzumab,Pertuzumab和化疗与Her2阳性乳腺癌(Kristine)的患者患有Trastuzumab Emtansine Plus Pertuzumab:随机,开放标签,多期,第3阶段试验
机译:VP6-2021:Imprassion050:Neoadjuvant atezolizumab + Pertuzumab + Trastuzumab +化疗(Neoadj A + pH + Ct)的第三阶段研究高风险,Her2阳性早期乳腺癌(EBC)